BlissCo is currently trading on the following stock exchanges:
Frankfurt Stock Exchange (FRA) as GQ4B:GR
BlissCo Enters Billion-Dollar Complementary and Alternative Medicine Market, Appoints Dr. Bryn Hyndman to Advisory Board
Complementary and alternative medicine market expected to generate $196.87 billion globally by 2025
Not for distribution in the U.S. or to U.S. newswire services.
Vancouver, British Columbia – June 20, 2018 – BlissCo Cannabis Corp. (CSE: BLIS) (FRA: GQ4B), (“BlissCo”) is pleased to announce that Dr. Bryn Hyndman, former medical director of Qi Integrated Health, is joining BlissCo’s advisory board.
Dr. Hyndman is a board-certified medical doctor with the Canadian College of Family Physicians (CCFP) and a naturopath.
“We are focused on building a strong ecosystem that includes partners such as Dr. Hyndman to enable us to establish the BlissCo brand as a premium craft cannabis product in the medical market and recreational market when it is legal,” said Damian Kettlewell, CEO of BlissCo Cannabis Corp.
A report by Grand View Research estimates that the complementary and alternative medicine market is expected to generate $196.87 billion in revenue globally by 2025.
“There is a gap in modern medicine; doctors are trained in chronic disease management and acute emergencies. Science has, until now, relied on double-blind, placebo-controlled trials where single drugs are studied in isolation, but there are a wide range of medical compounds in cannabis and they work synergistically. You can’t break down a plant and isolate these ingredients because you will lose its essence,” said Hyndman.
BlissCo’s cannabis extraction lab with the first Midas MIDAS XII Co2 extraction system in Canada will ensure that BlissCo safely extracts therapeutic cannabis terpenes along with the whole plant oils, offering a full spectrum of benefits to patients.
“We are excited to work with Dr. Hyndman to ensure that our patient care model and medical cannabis products are aligned. As well, BlissCo is pursuing clinical trial research partners and Dr. Hyndman’s experience with medical cannabis will assist us with the design and roll out of our first clinical trial,” said Kettlewell.
About BlissCo Cannabis Corp.
BlissCo Cannabis Corp. (CSE: BLIS) (FRA: GQ4B) owns, through its wholly-owned subsidiary BlissCo Holdings Ltd., a license to produce marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) which was originally granted on March 29, 2018.
BlissCo began growing medical cannabis in early May 2018 and applied to Health Canada to amend its ACMPR license to include cannabis oil production in early June 2018.
BlissCo is projected to have a sales license inspection from Health Canada in August 2018 and earn a sales license in late September or early October 2018 to sell dried cannabis.
BlissCo's value proposition is to be a brand focused high-volume distributor, processor and packager of medical cannabis and adult use cannabis when it is legal in Canada.
BlissCo will be processing and distributing cannabis purchased from multiple supply agreements and from cannabis grown at its own state of the art facility in Metro Vancouver, B.C. Currently, BlissCo has a two-year supply agreement with The Supreme Cannabis Company Inc (TSX.V: FIRE) to purchase 3,000 kilograms of premium whole dried cannabis flower.
BlissCo is currently exploring brand expansion opportunities in multiple international markets where medical cannabis is federally legal.
Management is focused on establishing BlissCo as an iconic Canadian cannabis brand.
On Behalf of the Board of Directors
BLISSCO CANNABIS CORP.
Damian Kettlewell, CEO, Founder & Chair
For further information please contact:
Ariel Jack Lewinski, Business Development & Investor Relations
This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively “forward-looking statements”). The use of any of the word “will” and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such forward-looking statements should not be unduly relied upon. This news release contains forward-looking statements and assumptions pertaining to the following: the ability to execute on our strategic plans and the impact on our future operations, capital expenditures, receipt of a cannabis oil license and a license to sell dried cannabis and other objectives. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The Company believes the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct. The Company does not undertake to update these forward-looking statements, except as required by law.
The CSE has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.
As Canada is primed as a global leader and first mover in the cannabis industry, BlissCo is uniquely poised in the rapidly growing multi-billion dollar market and in various international markets as cannabis regulations progress.
BlissCo, founded in 2013, is a Canadian vertically integrated cultivation, extraction and distribution focused cannabis brand that earned its Access to Cannabis for Medical Purposes Regulations (ACMPR) license to cultivate from Health Canada on March 29, 2018.
BlissCo's state-of-the-art production facility, located in Metro Vancouver, is purposefully designed as a hub for research, cultivation, processing, extraction, packaging and distribution.
Now with the ACMPR license to cultivate, BlissCo will commence its operation to harvest premium cannabis within its' urban facility in Metro Vancouver. BlissCo also has a multi-year supply agreement in place with a Canadian Licensed Producer of characteristically sun-grown premium medicinal cannabis to purchase supply in large volumes (news release). This premium bulk cannabis will be brought to our secure and pristine facility in British Columbia for processing and then be packaged for sale and distribution to our growing patient list when BlissCo has appropriately received its license for sale.
BlissCo was founded with the assistance of a team of advisors, including medical and naturopathic doctors, has intentionally engaged with the medical community to understand how to contribute to improved patient health with medicinal cannabis products. A large part of our strategy for growth centres on how to securely integrate and collaborate with the healthcare system.
The BlissCo team has deep domain expertise in the critical category success areas:
- Multi-province controlled substance distribution (BC and Alberta)
- Cultivation and product safety, consistency and security
- Indoor cultivation, controlled environments ensuring high standards & consistent products.
- Quality assurance, product safety, 3rd Party GMP Audits & Certifications.
Strategic partnership with the Supreme Cannabis Company
Trading on Canadian Securities Exchange (CSE:BLIS)
ACMPR License to Produce earned
Cannabis plant starting material to arrive at BlissCo's facility and growing commences.
ACMPR Cannabis Oil Extraction License application submitted
Sign agreement to export 720 kilograms of medical cannabis to Germany
ACMPR License to Sell application submitted
Sign supply agreement with GreenSeal Cannabis
Sign e-commerce and technology service agreement with Namaste Technologies (TSXV: N)
Confirmation of Readiness for Inspection received from Health Canada
Confirmation of Readiness for License from Health Canada
Close on purchasing facility for $2.4m
Earn Building Permit from Township of Langley
ACMPR Licensed Submitted